GDRXNasdaqServices-Computer Processing & Data PreparationFiscal year ends December 31
GoodRx Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.37+0.01 (+0.30%)
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- 84.3
- Dividend yield
- –
GoodRx Holdings, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prescription transactions revenue | $472.10M | $508.77M | $544.00M | $564.27M | $577.39M | $581.08M | $577.55M | $576.43M | $571.43M | $561.23M | $550.74M | $536.28M | 60.1% | -18.2% |
| Subscription revenue | $95.15M | $87.10M | $83.79M | $82.88M | $83.46M | $84.95M | $86.54M | $89.01M | $90.94M | $92.87M | $94.41M | $95.88M | 12.1% | +14.0% |
| Other revenue | $16.37M | $17.06M | $17.69M | $18.41M | $19.17M | $20.01M | $21.00M | $21.40M | $21.40M | $20.93M | $20.05M | $20.00M | 2.1% | -14.6% |
| Pharma Direct revenue | – | – | – | $135.09M | $119.85M | $111.38M | $107.24M | $103.55M | $91.31M | $89.14M | $85.07M | $85.57M | – | – |
By region
From the segment and revenue-disaggregation notes of GoodRx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.